Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Johnson & Johnson gets grant for surgical instrument for harvesting tendon grafts
Johnson & Johnson has been granted a patent for a surgical instrument designed for harvesting tendon grafts. The instrument features...
Guselkumab by Johnson & Johnson for Crohn's Disease (Regional Enteritis): Likelihood of Approval
Guselkumab is under clinical development by Johnson & Johnson and currently in Pre-Registration for Crohn's Disease (Regional Enteritis). According to...
Erdafitinib by Johnson & Johnson for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase II for Squamous Non-Small Cell Lung Cancer....
Daratumumab by Johnson & Johnson for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According...
Daratumumab by Johnson & Johnson for T-Cell Leukemia: Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for T-Cell Leukemia. According to GlobalData,...
Daratumumab by Johnson & Johnson for Primary Systemic Amyloidosis: Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Primary Systemic Amyloidosis. According to...
Daratumumab by Johnson & Johnson for Lymphoma: Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Lymphoma. According to GlobalData, Phase...
Daratumumab by Johnson & Johnson for Systemic Lupus Erythematosus: Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Systemic Lupus Erythematosus. According to...
Daratumumab by Johnson & Johnson for POEMS Syndrome (Crow-Fukase Syndrome): Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for POEMS Syndrome (Crow-Fukase Syndrome). According...
Daratumumab by Johnson & Johnson for Precursor B-Cell Lymphoblastic Leukemia-Lymphoma: Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. According...
JNJ-8543 by Johnson & Johnson for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
JNJ-8543 is under clinical development by Johnson & Johnson and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According...
JNJ-8543 by Johnson & Johnson for Follicular Lymphoma: Likelihood of Approval
JNJ-8543 is under clinical development by Johnson & Johnson and currently in Phase I for Follicular Lymphoma. According to GlobalData,...
JNJ-8543 by Johnson & Johnson for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval
JNJ-8543 is under clinical development by Johnson & Johnson and currently in Phase I for Splenic Marginal Zone B-Cell Lymphoma....
Daratumumab by Johnson & Johnson for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute...
Daratumumab by Johnson & Johnson for Lymphoblastic Lymphoma: Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Lymphoblastic Lymphoma. According to GlobalData,...
Ustekinumab by Johnson & Johnson for Pouchitis: Likelihood of Approval
Ustekinumab is under clinical development by Johnson & Johnson and currently in Phase III for Pouchitis. According to GlobalData, Phase...
JNJ-9280 by Johnson & Johnson for Inflammatory Bowel Disease: Likelihood of Approval
JNJ-9280 is under clinical development by Johnson & Johnson and currently in Phase I for Inflammatory Bowel Disease. According to...
Risk adjusted net present value: What is the current valuation of Johnson & Johnson's Gemcitabine?
Gemcitabine is a small molecule commercialized by Johnson & Johnson, with a leading Phase III program in Non Muscle Invasive...
Johnson & Johnson gets grant for expandable apparatus for electrophysiological sensing with staggered electrodes
Johnson & Johnson has been granted a patent for an apparatus designed for electrophysiological sensing. The apparatus includes a shaft...
Johnson & Johnson files patent for an apparatus for minimizing rotation of a staple driver
Johnson & Johnson has filed a patent for an apparatus that includes a staple, a body, a staple driver, and...